U.S. Stem Cell, Inc.

Equities

USRM

US90350U1007

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 03:46:59 2024-04-24 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		+9,900.00%	+9,900.00%

2023	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2023	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI

U.S. STEM CELL, INC. : Other Events (form 8-K)

May 15, 2020 at 04:03 pm EDT

Item 8.01 Other Events

U.S. Stem Cell, Inc. (the "Company") determined that it will be unable to meet the May 15, 2020 deadline to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020 (the "Form 10-Q") with the Securities and Exchange Commission, due to circumstances related to the COVID-19 pandemic.

Further, the Company has been following the recommendations of local health authorities to minimize exposure risk for its team members for the past several weeks, including the temporary closures of its corporate offices and having team members work remotely. These disruptions include, but are not limited to, the unavailability of key Company personnel required to prepare the Company's financial statements for the quarter ended March 31, 2020 due to suggested, and mandated, social quarantining and work from home orders.

The Company is relying on the following order issued by the Securities and Exchange Commission:

SECURITIES EXCHANGE ACT OF 1934 Release No. 34-88465 / March 25, 2020 ORDER

Latest news about U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
U.S. Stem Cell, Inc. Announces Management Changes	22-03-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	21-07-15	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	21-07-15	CI
U.S. Stem Cell, Inc.'s Equity Buyback announced on January 16, 2015, has expired.	20-12-30	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-06	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-11-06	CI
U.S. Stem Cell, Inc. Announces Resignation of Kristin Comella as a Member of the Board of Directors and Her Position as Chief Scientific Officer	19-09-06	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-08-07	CI
U.S. Stem Cell, Inc. Announces Earnings Results for the First Ended March 31, 2019	19-05-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-05-07	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	19-03-13	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-03-13	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	19-03-12	CI
U.S. Stem Cell, Inc. Announces Revenue Results for the Quarter and Financial Results for the Nine Months Ended September 30, 2018	18-11-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	18-11-07	CI
U.S. Stem Cell, Inc. Appoints Phil Posa as Senior Vice President of U.S. & International Sales	18-09-11	CI

Chart U.S. Stem Cell, Inc.

Duration

Period

More charts

Company Profile

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
U.S. STEM CELL, INC.	+9,900.00%	66.15K
VERTEX PHARMACEUTICALS INCORPORATED	-1.98%	104B
REGENERON PHARMACEUTICALS, INC.	+1.80%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.78%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.92%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.61%	13.98B
SAREPTA THERAPEUTICS, INC.	+33.65%	11.66B

Bio Therapeutic Drugs